Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
October 06, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of reducing rate of pulmonary exacerbationsLenabasum treatment had a favorable safety profile and was well-toleratedData to be presented at the upcoming North...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
May 22, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU ...
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
December 09, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
June 12, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
April 18, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 primary endpoint will now be aligned with that of previous Phase 2 studyACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was secondary endpoint in current...
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
December 17, 2018 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...